Morgan Lewis
Home > Our Thinking > Blogs > As Prescribed
Blogs

Editor

Maarika L. Kimbrell

pills As Prescribed

YOUR GO-TO SOURCE FOR ANALYSIS OF ISSUES AFFECTING THE PHARMA & BIOTECH SECTORS

340B Under the Microscope: Key Trends and Takeaways for 2025

By Stephen L. Forster , Sydney Menack , and Rachel L. Lamparelli
// June 10, 2025
The 340B Drug Pricing Program (the Program) has long been a cornerstone for healthcare providers seeking to deliver affordable care to underserved communities. However, as the regulatory and compliance landscape evolves, stakeholders—including covered entities, pharmaceutical manufacturers, and pharmacies—must navigate an increasingly complex array of legal requirements and enforcement trends.
Read More
Topics: Biologics, Drug Pricing, Pharmaceuticals

FDA’s Rare Disease Innovation Hub Releases Strategic Agenda: Implications for Stakeholders in 2025

By Maarika L. Kimbrell and Elizabeth Lawless
// February 05, 2025
Rare Disease Day
In response to calls from industry stakeholders for increased innovation, coordination, and tailored regulatory approaches to the development of treatments in rare disease, in recent years the US Food and Drug Administration (FDA) has established a number of rare disease-focused programs within the agency. Building on other recent FDA initiatives such as the Center for Drug Evaluation and Research (CDER) Accelerating Rare disease Cures (ARC) Program and the Center for Biologic Evaluation and Research (CBER) Rare Disease Program, FDA expanded its rare disease toolkit to include its Rare Disease Innovation Hub in 2024 to serve as a point of collaboration between CDER and CBER with the overarching goal of enhancing collaboration across centers to improve patient outcomes and addressing common challenges in drug development for rare diseases.
Read More
Topics: Biologics, CDER, Drugs, FDA, Rare Disease Day, Regulatory

Key Takeaways from the 2025 J.P. Morgan Healthcare Conference

By Laurie Burlingame , Jacqueline R. Berman , Stephen L. Forster , Luciana Griebel , and Maarika L. Kimbrell
// January 31, 2025
#JPMHC25
Several members of our firm’s life sciences team were on the ground at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco from January 13 to 16, 2025. It was an exciting and sunny four days, during which key players from across the life sciences industry gathered to engage in deal discussions and consider upcoming trends for the pharmaceutical, biotechnology, and healthcare industries. Although there was a notable increase in the level of security at the conference given recent events, the overall sentiment of the conference was one of optimism.
Read More
Topics: Biologics, Biotechnology, CMS, Drugs, FDA, Pricing, Regulatory

IP, Licensing, and M&A in the Life Sciences Industry: Trends to Watch in 2025

By Christopher J. Betti, Ph.D. , Christina A. MacDougall, Ph.D. , Benjamin H. Pensak , and Benjamin J. Stein
// January 17, 2025
The life sciences industry has long been at the forefront of innovation, and 2025 promises to continue this trajectory with exciting developments in intellectual property (IP), licensing, and mergers and acquisitions (M&A). As the sector navigates a dynamic landscape of scientific advancements, economic pressures, and regulatory changes, stakeholders are increasingly leveraging strategic transactions to gain a competitive edge.
Read More
Topics: Biologics, Biosimilars, Drugs, FDA, Healthcare, Innovative Drugs, Intellectual Property, Licensing, Life Sciences, Regulatory, Rulemaking

FDA Issues Long-Awaited Diversity Action Plan Guidance

By Maarika L. Kimbrell and Angela Silva
// August 19, 2024
Recognizing the importance of diversity and inclusivity in clinical trials, drug development, and regulatory decision-making, Congress amended the Federal Food, Drug, and Cosmetic Act (FDCA) in connection with the Food and Drug Omnibus Reform Act (FDORA) provisions of the Consolidated Appropriations Act of 2023, requiring sponsors of certain clinical studies of drugs, biological products, and medical devices to submit Diversity Action Plans to the FDA (FDCA Sections 505(z) and 520(g)(9)).
Read More
Topics: Biologics, Clinical Trials, Drugs, FDA, Guidance

Advertising and Promotion Considerations for Biologics, Biosimilars, and Interchangeables

By Maarika L. Kimbrell
// April 30, 2024
FDA recently issued a revised draft guidance titled Promotional Labeling and Advertising Considerations for Prescription Biological Reference Products, Biosimilar Products, and Interchangeable Biosimilar Products. This guidance provides specific recommendations for all three classes of products—biologics approved under 351(a) of the Public Health Service Act (PHS Act), and biosimilar products and interchangeable biosimilar products approved under 351(k) of the PHS Act—with respect to meeting FDA’s general accuracy and truthful and non-misleading standards that are applied to advertising and promotion of prescription drug products generally.
Read More
Topics: Biologics, Biosimilars, Guidance

Key Issues for Life Science Executives for 2024: JP Morgan Healthcare Conference Takeaways

By Jacqueline R. Berman , Laurie Burlingame , and Maarika L. Kimbrell
// February 15, 2024
It is hard to believe that we are already in February and it has been a month since the 42nd Annual JP Morgan Healthcare Conference in San Francisco wrapped. It was a packed four days in which the major players in the life sciences industry gathered to make deals, form relationships, and discuss upcoming trends for the pharmaceutical and biotechnology industry.
Read More
Topics: Biologics, Drugs, FDA, Financing

Pharma’s Almanac: Forecast at the Turn of the Year

By Jacqueline R. Berman and Maarika L. Kimbrell
// January 19, 2024
The ball has dropped on the healthcare and life sciences industry’s unique New Year tradition, the J.P. Morgan Healthcare Conference, so all eyes turn to 2024. To help define a path forward, Morgan Lewis FDA and healthcare partners Jacqueline Berman, Rebecca Dandeker, Maarika Kimbrell, and Kathleen Sanzo have assembled an in-depth report on drug and biologic developments at the FDA.
Read More
Topics: Biologics, Drugs, FDA, Manufacturing, Regulatory

FDA Guidance Confirms That Multiple Roads Lead to Substantial Evidence of Effectiveness

By Maarika L. Kimbrell
// November 14, 2023
Substantial evidence, the evidentiary standard for effectiveness established in 1962 by the US Federal Food, Drug, and Cosmetic Act (FD&C Act), is the measure against which all drugs and biologics are approved in the United States. This standard is, in large part, what makes the FDA’s approval standard often considered the worldwide “gold standard” for drug approvals. Now, recent draft guidance issued by FDA looks to refine this standard even further.
Read More
Topics: Biologics, Clinical Trials, Drugs, FDA

Executive Order Outlines New Federal Biotechnology/Manufacturing Goals

By Jacqueline R. Berman and Kathleen M. Sanzo
// September 16, 2022
President Joseph Biden issued an “Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy” (EO) on September 12. Under this EO, the president aims to “advance biotechnology and biomanufacturing towards innovative solutions in health, climate change, energy, food security, agriculture, supply chain resilience, and national and economic security” through a multipronged and collaborative approach.
Read More
Topics: Biologics, Drugs, Manufacturing
  • 1
  • 2

WHO WE FOLLOW

  • FDA
  • FDA Voices
  • CDC
  • CMS
  • CMS Blog
  • NIH
  • BIO
  • FDLI
  • PhRMA
  • RAPS

WANT TO RECEIVE NOTIFICATIONS?

  • Subscribe
  • RSS Feed

INFORMATION

  • About Us & Contributors

© 2025 Morgan, Lewis & Bockius LLP. Morgan Lewis is a registered trademark of Morgan, Lewis & Bockius LLP. All rights reserved.